Stefanos Theoharis

Stefanos is a senior executive and consultant with more than 15 years of BD and R&D experience in pharma and biotech, with a focus on cell and gene therapy. This includes his roles as CBO at Bone Therapeutics and Senior Vice-President at Cell Medica, both clinical-stage biotech company, where he expanded the companies’ cell therapy platforms and pipelines through strategic partnerships. Prior to Cell Medica, Stefanos was Chief Business Officer at apceth GmbH, a company developing genetically engineered mesenchymal stromal (MSC) cell products and also acting as a contract manufacturer in the ATMP space. He led all apceth’s business development activities, including in- and out-licensing and service contracts negotiations. He also held positions as Head of Business Development at the antisense RNA drug specialist Antisense Pharma (now Isarna), and Director Business Development at Roche, focused on partnering activities in emerging science and technologies. Stefanos also worked at Lazard, the global investment bank, advising to a variety of life sciences firms on M&As and financing transactions. Stefanos achieved an MSc. in Molecular Medicine and a PhD in Pathology and Immunology from Imperial College London